Cystitis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
m Bot: Removing from Primary care |
|||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cystitis}} | {{Cystitis}} | ||
{{CMG}} {{AE}} {{USAMA}} | |||
==Overview== | |||
Cystitis may present as a nonthreatening condition but can be a significant economic burden. According to an estimate the treatment of cystitis leads to a mean direct cost of 236 pounds per episode. Aetiology and pathogen specific therapies are much more cost effective than broad spectrum therapies used for symptomatic treatment. [[Hyaluronan]] therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a [[Urinary tract infection]].<ref name="pmid23921624">{{cite journal| author=Riedl C, Engelhardt P, Schwarz B| title=Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines. | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 10 | pages= 737-42 | pmid=23921624 | doi=10.1007/s40261-013-0119-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23921624 }} </ref><ref name="pmid23475540">{{cite journal| author=Ciani O, Grassi D, Tarricone R| title=An economic perspective on urinary tract infection: the "costs of resignation". | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 4 | pages= 255-61 | pmid=23475540 | doi=10.1007/s40261-013-0069-x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23475540 }} </ref> | |||
==Cost-Effectiveness of Therapy== | |||
*Hyaluronan is very cost effective in the long run when compared with all alternative treatments, despite initial high costs.<ref name="pmid23921624">{{cite journal| author=Riedl C, Engelhardt P, Schwarz B| title=Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines. | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 10 | pages= 737-42 | pmid=23921624 | doi=10.1007/s40261-013-0119-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23921624 }} </ref> | |||
*[[Amoxicillin]] is almost two times cheaper than [[Aminoglycosides]] when used in the treatment of uncomplicated Cystitis.<ref name="pmid23475540">{{cite journal| author=Ciani O, Grassi D, Tarricone R| title=An economic perspective on urinary tract infection: the "costs of resignation". | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 4 | pages= 255-61 | pmid=23475540 | doi=10.1007/s40261-013-0069-x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23475540 }} </ref> | |||
*First and Second generation [[Cephalosporins]] are considered to be cost effective in treating lower urinary tract infections empirically.<ref name="pmid10911441">{{cite journal| author=Jakobi P, Goldstick O, Finkelstein R, Itzkovitz-Eldor J| title=[Empirical treatment of urinary tract infections in the delivery room--findings and desires]. | journal=Harefuah | year= 1998 | volume= 135 | issue= 9 | pages= 344-7, 408 | pmid=10911441 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10911441 }} </ref> | |||
*The use of Fluoroquinolone and nitrofurantoin is not cost effective.<ref name="pmid11784218">{{cite journal| author=Huang ES, Stafford RS| title=National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. | journal=Arch Intern Med | year= 2002 | volume= 162 | issue= 1 | pages= 41-7 | pmid=11784218 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11784218 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | |||
[[Category:Emergency medicine]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category: | [[Category:Infectious disease]] | ||
[[Category:Nephrology]] | [[Category:Nephrology]] | ||
[[Category: | [[Category:Urology]] | ||
Latest revision as of 21:12, 29 July 2020
|
Cystitis Microchapters | |
|
Diagnosis | |
|
Treatment | |
|
Case Studies | |
|
Cystitis cost-effectiveness of therapy On the Web | |
|
American Roentgen Ray Society Images of Cystitis cost-effectiveness of therapy | |
|
Risk calculators and risk factors for Cystitis cost-effectiveness of therapy | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
Cystitis may present as a nonthreatening condition but can be a significant economic burden. According to an estimate the treatment of cystitis leads to a mean direct cost of 236 pounds per episode. Aetiology and pathogen specific therapies are much more cost effective than broad spectrum therapies used for symptomatic treatment. Hyaluronan therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a Urinary tract infection.[1][2]
Cost-Effectiveness of Therapy
- Hyaluronan is very cost effective in the long run when compared with all alternative treatments, despite initial high costs.[1]
- Amoxicillin is almost two times cheaper than Aminoglycosides when used in the treatment of uncomplicated Cystitis.[2]
- First and Second generation Cephalosporins are considered to be cost effective in treating lower urinary tract infections empirically.[3]
- The use of Fluoroquinolone and nitrofurantoin is not cost effective.[4]
References
- ↑ 1.0 1.1 Riedl C, Engelhardt P, Schwarz B (2013). "Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines". Clin Drug Investig. 33 (10): 737–42. doi:10.1007/s40261-013-0119-4. PMID 23921624.
- ↑ 2.0 2.1 Ciani O, Grassi D, Tarricone R (2013). "An economic perspective on urinary tract infection: the "costs of resignation"". Clin Drug Investig. 33 (4): 255–61. doi:10.1007/s40261-013-0069-x. PMID 23475540.
- ↑ Jakobi P, Goldstick O, Finkelstein R, Itzkovitz-Eldor J (1998). "[Empirical treatment of urinary tract infections in the delivery room--findings and desires]". Harefuah. 135 (9): 344–7, 408. PMID 10911441.
- ↑ Huang ES, Stafford RS (2002). "National patterns in the treatment of urinary tract infections in women by ambulatory care physicians". Arch Intern Med. 162 (1): 41–7. PMID 11784218.